CA Patent

CA2916564C — Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Assigned to Global Blood Therapeutics Inc · Expires 2023-02-28 · 3y expired

What this patent protects

Disclosed are crystalline free base ansolvate and solvate forms of 2-hydroxy-6-((2-1-isopropy1-1H-pyrazol-5-yl)pyridine-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form 11 and Material N. These forms are used to prepare the solid crystalline free base…

USPTO Abstract

Disclosed are crystalline free base ansolvate and solvate forms of 2-hydroxy-6-((2-1-isopropy1-1H-pyrazol-5-yl)pyridine-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form 11 and Material N. These forms are used to prepare the solid crystalline free base of Compound 1 which may be used to increase oxygen affinity of hemoglobin in a subject, treating a disorder mediated by hemoglobin, or treating sickle cell disease.

Drugs covered by this patent

Patent Metadata

Patent number
CA2916564C
Jurisdiction
CA
Classification
—
Expires
2023-02-28
Drug substance claim
No
Drug product claim
No
Assignee
Global Blood Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.